Cholangiocarcinoma

The AJMC® Cholangiocarcinoma compendium is a comprehensive resource for clinical news and expert insights about this rare cancer of the bile duct.

Latest News

image of liver highlighted inside human body
Postoperative TACE Prolongs RFS in Patients With Combined Hepatocellular-Cholangiocarcinoma

December 19th 2022

Overall survival for patients with combined hepatocellular-cholangiocarcinoma is poor, but those who received adjuvant transarterial chemoembolization (TACE) after surgery had a prolonged recurrence-free survival (RFS).

graphic of liver
Case Report Details Diagnostic Imaging for Rare Distal Cholangiocarcinoma Case

December 15th 2022

doctor and patient meeting in an exam room
Surveillance Program Ineffective at Detecting Cholangiocarcinoma Early Enough for Benefit in Patients With PSC

November 30th 2022

Rendering of DNA helix
Study: FGFR mRNA Overexpression Occurs Frequently for Those With Cholangiocarcinoma

November 29th 2022

image of a liver with DNA strands
FGFR Inhibitors Show Promise in Cholangiocarcinoma but Face Acquired Resistance

November 25th 2022

More News

Image of the liver and pancreas
June 9th 2022

Combining Techniques Boosts Diagnostic Sensitivity in Intrahepatic Cholangiocarcinoma

Jared Kaltwasser
Hepatobiliary-phase enhanced imaging outperformed diffusion-weighted imaging in distinguishing intrahepatic mass-forming cholangiocarcinoma, but the accuracy is greater when these methods are used in tandem.
Adjuvant Therapy Shows No Significant Benefits After Cholangiocarcinoma Resection
June 3rd 2022

Adjuvant Therapy Shows No Significant Benefits After Cholangiocarcinoma Resection

Rose McNulty
A retrospective study found low treatment adherence and no significant benefits to adjuvant chemotherapy or chemoradiotherapy following cholangiocarcinoma resection.
lymphatic system
May 29th 2022

Study Finds Adjuvant Therapy Beneficial for Distal Cholangiocarcinoma With Lymph Node Metastasis

Rose McNulty
Recurrence is common in patients with distal cholangiocarcinoma, even after curative surgical resection. In a recent study, postoperative adjuvant therapy correlated with improved survival, but only in certain patients.
Alcohol Use, Disease-Free Survival Predictors in Patients With Recurrence of Intrahepatic Cholangiocarcinoma
May 22nd 2022

Alcohol Use, Disease-Free Survival Predictors in Patients With Recurrence of Intrahepatic Cholangiocarcinoma

AJMC Staff
The study from China sought to evaluate clinical factors associated with survival after recurrence following surgery in ICC.
Biliary Tract Cancer Rates Vary by Country; Prevention Efforts Needed
May 21st 2022

Biliary Tract Cancer Rates Vary by Country; Prevention Efforts Needed

Mary Caffrey
Authors wrote that their analysis was the first to combine incidence and mortality of overall BTC, and its anatomic subtypes, into a single study
City of Hope Faculty Honored for Achievements in Clinical Surgery, Promotion of Women in Cancer Science
May 14th 2022

City of Hope Faculty Honored for Achievements in Clinical Surgery, Promotion of Women in Cancer Science

AJMC Staff
Yuman Fong, MD, received the 2022 Flance-Karl Award from the American Surgical Association (ASA), and Leslie Bernstein, PhD, received the Margaret L. Kripke Legend Award for Promotion of Women in Cancer Medicine and Cancer Science.
Treating iCCA With Chemo Pump Can Be as Effective as Surgery, JAMA Study Finds
May 11th 2022

Treating iCCA With Chemo Pump Can Be as Effective as Surgery, JAMA Study Finds

Mary Caffrey
Cholangiocarcinoma (CCA), or bile duct cancer, is classified by its location, with intrahepatic CCA (iCCA) referring to those cancers that form in bile ducts within the liver.
Image of doctor and patient
May 5th 2022

Screen Patients With CUP for Intrahepatic Cholangiocarcinoma, Study Suggests

Jared Kaltwasser
In patients with liver involvement, intrahepatic cholangiocarcinoma was a common diagnosis among some patients with cancer of unknown primary (CUP).
European Effort Will Make Cholangiocarcinoma Treatment Info Available in Multiple Languages
May 2nd 2022

European Effort Will Make Cholangiocarcinoma Treatment Info Available in Multiple Languages

Mary Caffrey
The project seeks to develop materials explaining chemotherapy regimens for patients with biliary tract cancers and then translate these materials into “standardized, high-quality, free, and easily accessible resources."
blurred medical setting
April 25th 2022

Cholangiocarcinoma Incidence Doubled in Publicly Funded Health Care System in Texas

Allison Inserro
Patients were younger and had more advanced disease at diagnosis, according to the study.
Image of bile ducts
April 18th 2022

CXCR2 Signaling Appears to Have Implications for Cholangiocarcinoma

Jared Kaltwasser
Expression of the chemokine receptor was linked with better overall survival.
Preclinical Data at AACR Show CSP May Be Broad Target in Cholangiocarcinoma
April 13th 2022

Preclinical Data at AACR Show CSP May Be Broad Target in Cholangiocarcinoma

Mary Caffrey
Researchers presented results for ZB131, a monoclonal antibody that would target cancer-specific plectin (CSP); experiments with mice showed this may be present in more than 80% of the most common types of cholangiocarcinoma.
red cross
April 10th 2022

Study Characterizes Peripheral Nerve Invasion in HCCA With Novel WHLS Method

Rose McNulty
Analyzing whole-mount histologic large sections is not a new practice, but a new strategy was needed to fully characterize peripheral nerve invasion in hilar cholangiocarcinoma.
Understanding the Tumor Microenvironment of Cholangiocarcinoma
April 7th 2022

Understanding the Tumor Microenvironment of Cholangiocarcinoma

Mary Caffrey
The authors found that the relationship between immunosuppressive cells and effector T cells in hilar and distal cholangiocarcinoma has important implications for treatment, in that the tumor microenvironment would likely need to be primed for a treatment strategy to be effective.
Image of bile duct cancer
April 5th 2022

Case Report Highlights Malignancy Challenges Post Liver Transplant

Jared Kaltwasser
In this case, a patient died 18 months following his transplant after developing de novo intrahepatic cholangiocarcinoma.
FOLFOX Delivery Method Could Offer Option in Unresectable Intrahepatic Cholangiocarcinoma
March 29th 2022

FOLFOX Delivery Method Could Offer Option in Unresectable Intrahepatic Cholangiocarcinoma

Mary Caffrey
The authors say delivering FOLFOX via transarterial infusion could be a “perfect option for treating intrahepatic cholangiocarcinoma before patients receive targeted therapy, immunotherapy, or radiotherapy.
BITCOIN: FGFR2/3 Alterations Linked to Better Survival in Cholangiocarcinoma
March 26th 2022

BITCOIN: FGFR2/3 Alterations Linked to Better Survival in Cholangiocarcinoma

Mary Caffrey
The study by the Veneto Institute of Oncology (IOV) in Padua, Italy, examined 286 patients for genomic mutations in cholangiocarcinoma as well as survival status.
KRAS Mutations Linked to Aggressive Tumors, Poor Survival in Cholangiocarcinoma
March 23rd 2022

KRAS Mutations Linked to Aggressive Tumors, Poor Survival in Cholangiocarcinoma

Mary Caffrey
A recommendation to test for the mutation aligns with calls to identify biomarkers in cholangiocarcinoma to guide treatment.
Study Identifies Markers for Presurgical Staging System in Cholangiocarcinoma
March 12th 2022

Study Identifies Markers for Presurgical Staging System in Cholangiocarcinoma

Mary Caffrey
A study from Japan identifies markers for a presurgical staging system in intrahepatic cholangiocarcinoma, with results on par with an existing postsurgical staging system.
Shroff: Multiple Targets in Cholangiocarcinoma Make Biomarker Testing Essential
February 28th 2022

Shroff: Multiple Targets in Cholangiocarcinoma Make Biomarker Testing Essential

Mary Caffrey
Rachna Shroff, MD, associate dean of clinical and translational research and associate professor of medicine at the University of Arizona, offered a review of early-stage research in her talk, “The Hottest Targeted Therapies on the Horizon for Cholangiocarcinoma.”
Clinical, Scientific Updates at CCF 2022 Highlight Advances in Cholangiocarcinoma
February 27th 2022

Clinical, Scientific Updates at CCF 2022 Highlight Advances in Cholangiocarcinoma

Mary Caffrey
The co-chairs of the Cholangiocarcinoma Foundation 2022 meeting, Lipika Goyal, MD, MPhil, of Harvard and Massachusetts General Hospital, and Jesper B, Andersen, PhD, of the University of Copenhagen, Denmark, reviewed clinical and scientific developments.
Pemazyre
February 21st 2022

How FGFR Inhibitors Work in Cholangiocarcioma, and What Comes Next

Mary Caffrey
Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of pemigatinib, the first targeted therapy approved by FDA, only 15% to 25% of patients with CCA were “fit enough to receive second-line chemotherapy.”
bile duct cancers
February 20th 2022

What Makes Recurrence More Likely After Hepatectomy in Intrahepatic Cholangiocarcinoma?

Mary Caffrey
A new study in the Annals of Surgical Oncology finds that recurrence of intrahepatic cholangiocarinoma after hepatectomy can be 50% to 70%, and about half these recurrences happen within 2 years. The review sought to identify the factors that can predict the return of cancer within a 2-year span.
FGFR2 fusion
February 13th 2022

What Do Real-world Data Say About FGFR2 Status and PFS, OS in Cholangiocarcinoma?

Mary Caffrey
The presence of FGFR2 alterations occurs almost exclusively in intrahepatic cholangiocarcinoma (iCCA) and is seen in 10% to 16% of patients. A question examined in abstracts over the past year has been whether FGFR2 alterations affect survival in those patients who receive systemic chemotherapy for iCCA.
Largest Registry Study of Cholangiocarcinoma Discusses Challenges of Late Diagnosis
February 12th 2022

Largest Registry Study of Cholangiocarcinoma Discusses Challenges of Late Diagnosis

Mary Caffrey
A study published on World Cholangiocarcinoma Day outlines characteristics of disease subtypes and the strong links to lifestyle factors, such as obesity and alcohol use.
TOPAZ-1: Phase 3 Study Finds Durvalumab in Biliary Tract Cancer Significantly Improves OS, PFS Compared With Chemo Alone
January 18th 2022

TOPAZ-1: Phase 3 Study Finds Durvalumab in Biliary Tract Cancer Significantly Improves OS, PFS Compared With Chemo Alone

Mary Caffrey
There has not been a change in the standard of care in this type of cancer in a decade, according to an expert from ASCO.
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo